129 related articles for article (PubMed ID: 23448458)
1. Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.
Tuttolomondo A
Curr Pharm Des; 2013; 19(33):5972-3. PubMed ID: 23448458
[No Abstract] [Full Text] [Related]
2. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
[No Abstract] [Full Text] [Related]
3. Gastroenterological complications of Anderson-Fabry disease.
Buda P; Książyk J; Tylki-Szymanska A
Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
[TBL] [Abstract][Full Text] [Related]
4. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
Machann W; Breunig F; Weidemann F; Sandstede J; Hahn D; Köstler H; Neubauer S; Wanner C; Beer M
Eur J Heart Fail; 2011 Mar; 13(3):278-83. PubMed ID: 21149315
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease: developments in diagnosis and treatment.
Mehta AB
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous complications of Anderson-Fabry disease.
Giuseppe P; Daniele R; Rita BM
Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
[TBL] [Abstract][Full Text] [Related]
7. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
9. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
10. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
Das AM; Naim HY
Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
[TBL] [Abstract][Full Text] [Related]
11. [Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies].
Pisani A; Visciano B; Capuano I; Mancini A; Riccio E
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832445
[TBL] [Abstract][Full Text] [Related]
12. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
[TBL] [Abstract][Full Text] [Related]
13. Searching for an additional treatment to slowing the progression of Fabry disease.
Ravarotto V; Carraro G; Simioni F; Bertoldi G; Pagnin E; Calò LA
Minerva Med; 2019 Apr; 110(2):176-178. PubMed ID: 30821433
[No Abstract] [Full Text] [Related]
14. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
Kampmann C; Kalkum G; Beck M; Whybra C
Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
[No Abstract] [Full Text] [Related]
15. Authors’ reply.
Goláň L; Chang P
Drug Des Devel Ther; 2015; 9():5875. PubMed ID: 26918251
[No Abstract] [Full Text] [Related]
16. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.
Ortiz A; Sanchez-Niño MD
Drug Des Devel Ther; 2015; 9():5873-4. PubMed ID: 26586938
[No Abstract] [Full Text] [Related]
17. Endocytotic internalization of alpha-2-macroglobulin: alpha-galactosidase conjugate by cultured fibroblasts derived from Fabry hemizygote.
Osada T; Kuroda Y; Ikai A
Biochem Biophys Res Commun; 1987 Jan; 142(1):100-6. PubMed ID: 2434088
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity.
Allen LE; Cosgrave EM; Kersey JP; Ramaswami U
Br J Ophthalmol; 2010 Dec; 94(12):1602-5. PubMed ID: 20576773
[TBL] [Abstract][Full Text] [Related]
19. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
Koh S; Sakai N; Maeda N; Nishida K
Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
[No Abstract] [Full Text] [Related]
20. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
Lenders M; Schmitz B; Brand SM; Brand E
Orphanet J Rare Dis; 2018 Sep; 13(1):171. PubMed ID: 30268124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
